Creatine monohydrate in myotonic dystrophy

Walter, Maggie C.; Reilich, Peter; Lochmüller, Hanns; Kohnen, R.; Schlotter, Beate; Haŭtmann, Hŭbert; Dunkl, Elmar; Pongratz, D.; Müller‐Felber, Wolfgang

doi:10.1007/s00415-002-0923-x

Cited by 52 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the effects of Cr supplementation on measures of strength and function are equivocal. Cr supplementation had no effect on HGS, IKES, a timed 30‐foot walk (30′W), or a timed 4‐step climb test (SCT) in osteoarthritic patients following surgery , while in patients with muscular dystrophy, supplementation with Cr failed to improve HGS or IKES , or function (SCT, 30′W, and time taken to stand from supine) . Furthermore, despite eliciting an increase in LM, no improvement in ankle dorsiflexion strength was reported by Sakkas et al in 20 HIV‐positive men following 2 weeks of Cr supplementation.…”

Section: Discussionmentioning

confidence: 95%

Can Creatine Supplementation Improve Body Composition and Objective Physical Function in Rheumatoid Arthritis Patients? A Randomized Controlled Trial

Wilkinson

Lemmey

Jones

et al. 2016

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Rheumatoid cachexia (muscle wasting) in rheumatoid arthritis (RA) patients contributes to substantial reductions in strength and impaired physical function. The objective of this randomized controlled trial was to investigate the effectiveness of oral creatine (Cr) supplementation in increasing lean mass and improving strength and physical function in RA patients. Methods. In a double-blind design, 40 RA patients were randomized to either 12 weeks' supplementation of Cr or placebo. Body composition (dual x-ray absorptiometry and bioelectrical impedance spectroscopy [BIS]), strength, and objectively assessed physical function were measured at baseline, day 6, week 12, and week 24. Data analysis was performed by analysis of covariance. Results. Cr supplementation increased appendicular lean mass (ALM; a surrogate measure of muscle mass) by mean 6 SE 0.52 6 0.13 kg (P 5 0.004 versus placebo), and total LM by 0.60 6 0.37 kg (P 5 0.158). The change in LM concurred with the gain in intracellular water (0.64 6 0.22 liters; P 5 0.035) measured by BIS. Despite increasing ALM, Cr supplementation, relative to placebo, failed to improve isometric knee extensor strength (P 5 0.408), handgrip strength (P 5 0.833), or objectively assessed physical function (P 5 0.335-0.764). Conclusion. In patients with RA, Cr supplementation increased muscle mass, but not strength or objective physical function. No treatment-related adverse effects were reported, suggesting that Cr supplementation may offer a safe and acceptable adjunct treatment for attenuating muscle loss; this treatment may be beneficial for patients experiencing severe rheumatoid cachexia.

show abstract

Section: Discussionmentioning

confidence: 95%

Can Creatine Supplementation Improve Body Composition and Objective Physical Function in Rheumatoid Arthritis Patients? A Randomized Controlled Trial

Wilkinson

Lemmey

Jones

et al. 2016

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

Myotonic Dystrophy Type 1

Die-Smulders

Jennekens

Höweler

2005

Management of Genetic Syndromes

View full text Add to dashboard Cite

Myotonic dystrophy type 1 is characterized by muscle weakness, myotonia, and multiple organ complications. Age of onset is very variable and is an important factor determining the clinical picture. The management is difficult due to the chronic course, the variability of symptoms, and the personality traits of myotonic dystrophy type 1 individuals. Annual follow‐up is recommended, using a standardized protocol such as the Cardiff Myotonic Dystrophy Muscle Clinic Record. Furthermore, education of affected individuals and their relatives and active dissemination of management protocols are important.

show abstract